Topic: FDA warning letter
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
The FDA has issued a warning letter for a Sichuan Friendly Pharmaceutical plant at Neijiang, Sichuan.
Foshan Jinxiong Technology has been on an import alert list since February, banning all of its products from entering the U.S.
In just their second wrist-slap of the year, the FDA's promo police chastised Pfizer for leaving risk information out of an Estring video.
Takeda investors worry about Shire's hemophilia products; Biocon's biosimilars plant clears the FDA; C-Bridge Capital invests $35 million in Nuance.
A Chinese API maker that was put on the FDA’s import alert list in March has now been given an FDA warning letter.
Celltrion says its biosimilars for Herceptin and Rituxan could be approved this year after it made plant improvements to resolve and FDA warning letter.
FDA clears Sun Pharma's key Halol plant, Eisai builds a new drug discovery center for Alzheimer's, opposition to the Takeda-Shire deal gains support.
The FDA issued Taiwan Biotech a warning letter, citing a number of issues with the company’s quality-control unit.
After more than two years of intense effort, Sun Pharma has returned its key plant to the good graces of the FDA.